NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of DexCom, Inc. (NASDAQ: DXCM). Shareholders who purchased shares of DXCM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/dexcom-inc-loss-submission-form-2/?id=178599&from=3 CLASS PERIOD: January 8, 2024 to ...

Core Viewpoint - Ademi & Fruchter LLP is investigating potential securities fraud claims against DexCom, Inc. due to inaccurate statements regarding its business operations and the quality of its products [1][2]. Group 1: Investigation Details - The investigation centers on DexCom's claims about its G7 blood glucose monitor, asserting it was of high quality and manufactured with FDA-approved materials [2]. - Reports indicate that DexCom altered the sensor membrane coating material from a third-party supplier to an in-house formulation without notifying the FDA or investors, which deviated from the FDA-approved formulation [2]. - The investigation period spans from January 8, 2024, to September 17, 2025 [2].

Accessibility StatementSkip Navigation Shareholders who purchased shares of DXCM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: CONTACT:The Gross Law Firm15 West 38th Street, 12th floorNew York, NY, 10018Email: [email protected] Phone: (646) 453-8903 NEW YORK, Nov. 24, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders ...

Investment Strategy - Investing in stocks for a long period, such as 30 years, can lead to significant wealth accumulation through compounding returns [1] - A well-defined strategy and commitment to endure market fluctuations are essential for investors [1][2] - Understanding personal risk tolerance and spreading investments across various asset classes and sectors is crucial for capitalizing on diverse growth opportunities [2] Healthcare Industry Opportunities - The healthcare industry offers substantial opportunities for notable portfolio returns over decades [3] - Vertex Pharmaceuticals and DexCom are highlighted as two companies with strong long-term growth potential in the healthcare sector [3] Vertex Pharmaceuticals - Vertex Pharmaceuticals holds a near monopoly in the cystic fibrosis drug market, generating significant revenue and strong free cash flow [4] - The company’s patents for key cystic fibrosis drugs extend into the late 2030s, providing a stable revenue foundation [4] - Vertex is expanding its portfolio beyond cystic fibrosis into other serious diseases, including a gene-editing therapy for sickle cell disease and a non-opioid pain management solution [5][6] - Vertex reported a total revenue of $3.08 billion for Q3 2025, an 11% year-over-year increase, with a net income of $1.1 billion [10] DexCom - DexCom is the leading manufacturer of continuous glucose monitoring devices, serving a growing global population with diabetes [11] - The company has a significant market share in the U.S. CGM market but has vast untapped opportunities, as less than 1% of Type 1 diabetics currently use CGM technology [12] - DexCom's revenue grew by 22% in Q3, with U.S. revenue increasing by 21% year-over-year and international revenue rising by 22% [16]

Core Viewpoint - Rosen Law Firm is encouraging investors of DexCom, Inc. to secure legal counsel before the December 29, 2025 deadline for a securities class action related to alleged misleading statements and health risks associated with the company's glucose monitoring systems [2][3][6]. Group 1: Class Action Details - The class action pertains to investors who purchased DexCom securities between July 26, 2024, and September 17, 2025 [2]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3]. - A lead plaintiff must file a motion with the court by December 29, 2025, to represent other class members [4]. Group 2: Allegations Against DexCom - The lawsuit claims that DexCom made unauthorized design changes to its G6 and G7 continuous glucose monitoring systems, which compromised their reliability and posed health risks to users [6]. - Defendants allegedly overstated the enhancements and reliability of the G7 devices while downplaying the severity of the issues [6]. - The situation has led to increased regulatory scrutiny and potential legal, reputational, and financial harm for DexCom [6]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company [5]. - The firm was ranked No. 1 for securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions for investors [5]. - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in litigation [5].

Core Viewpoint - Securities class action lawsuits have been filed against DexCom, Inc. for alleged misleading statements and undisclosed risks related to its G6 and G7 continuous glucose monitoring systems during the specified Class Period from January 8, 2024, to September 17, 2025 [1][2]. Summary by Sections Allegations Against DexCom - Defendants allegedly made false or misleading statements regarding unauthorized design changes to the G6 and G7 systems, which compromised their reliability and posed health risks to users [2]. - The enhancements claimed for the G7 device were reportedly overstated, and the company downplayed the severity of issues related to the G7 devices [2]. - These actions have led to increased regulatory scrutiny and potential legal, reputational, and financial harm for DexCom [2]. Legal Process for Investors - Investors who suffered losses can seek to be appointed as lead plaintiffs by December 26, 2025, or remain absent class members [3]. - The lead plaintiff will represent the interests of all class members and select legal counsel for the case [3]. Firm Background - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has a reputation for recovering significant amounts for victims of corporate misconduct [4].

Core Viewpoint - Securities class action lawsuits have been filed against DexCom, Inc. for alleged misleading statements and undisclosed material changes to its glucose monitoring systems during the specified Class Period [1][2]. Allegations Against DexCom - Defendants allegedly made false and misleading statements regarding unauthorized design changes to the G6 and G7 continuous glucose monitoring systems, which compromised their reliability and posed health risks to users [2]. - The enhancements claimed for the G7 device were overstated, and the company downplayed the severity of issues related to the adulterated devices [2]. - These actions have led to increased regulatory scrutiny and potential legal, reputational, and financial harm for DexCom [2]. Lead Plaintiff Process - Investors in DexCom have until December 26, 2025, to seek appointment as lead plaintiff representatives in the class action, which involves directing the litigation on behalf of all class members [3]. - The lead plaintiff is typically the investor or group of investors with the largest financial interest in the case [3]. Contact Information - Kessler Topaz Meltzer & Check, LLP encourages affected DexCom investors to reach out for more information regarding the lawsuits [4].

Core Insights - DexCom has received FDA clearance for its CGM-integrated basal insulin dosing optimizer, Dexcom Smart Basal, specifically for adults with Type 2 diabetes using glargine U-100 long-acting insulin therapy [1][8] - The software will utilize data from DexCom's G7 15 day CGM sensor to provide personalized daily insulin dose recommendations, enhancing the effectiveness of long-acting insulin therapy [2][9] - Despite the FDA clearance, DexCom's stock has declined by 23.2% this year, contrasting with the industry's growth of 0.6% and the S&P 500's gain of 13.5% [3] Product Details - Dexcom Smart Basal is the first titration software that integrates with a CGM sensor to optimize basal insulin doses, starting with an initial dose set by healthcare providers [1][6] - The software analyzes CGM readings to provide personalized recommendations, adjusting doses based on glucose levels and offering alerts for low glucose to prevent hypoglycemic episodes [9][10] - The feature is expected to improve adherence to insulin therapy and reduce the workflow for healthcare providers by minimizing manual input and office visits [10] Market Performance - Following the FDA clearance, DexCom's stock fell by 0.7% on November 19, indicating ongoing pressure on gross margins despite the positive regulatory news [3][4] - The introduction of Dexcom Smart Basal is anticipated to boost demand for the G7 15 day sensor among Type 2 diabetes patients [4] Competitive Landscape - DexCom currently holds a Zacks Rank of 3 (Hold), while other medical stocks like Medpace Holdings, Globus Medical, and Masimo have higher rankings, indicating stronger performance in the market [11] - Medpace has shown a significant earnings growth rate of 17.1% for 2025, outperforming the industry average of 16.6% [12] - Globus Medical and Masimo also reported strong earnings, with adjusted EPS exceeding consensus estimates, highlighting competitive performance in the medical sector [12][13]

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of DexCom, Inc. regarding a class action lawsuit alleging that the company made misleading statements about its glucose monitoring products, the G6 and G7, which were not authorized by the FDA and posed health risks to users [1]. Group 1: Allegations Against DexCom - The lawsuit claims that DexCom made unauthorized design changes to the G6 and G7 glucose monitoring devices, which rendered them less reliable than previous versions [1]. - It is alleged that the enhancements to the G7's reliability, accuracy, and functionality were overstated, and the company downplayed the severity of the issues related to the devices [1]. - The complaint suggests that these actions increased the risk of regulatory scrutiny and potential legal, reputational, and financial harm to DexCom [1]. Group 2: Class Action Details - The class period for the lawsuit is defined as January 8, 2024, to September 17, 2025, and shareholders are encouraged to register for participation [2]. - The deadline for shareholders to seek lead plaintiff status is December 26, 2025, and there is no cost to participate in the case [2]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the lifecycle of the case [2].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of DexCom, Inc. regarding a class action lawsuit alleging misleading statements and undisclosed material changes to the company's glucose monitoring products, G6 and G7, which may have health implications for users [1][3]. Group 1: Allegations - The complaint claims that DexCom made unauthorized design changes to the G6 and G7 glucose monitoring products, which rendered them less reliable and posed health risks to users [3]. - It is alleged that the enhancements to the G7's reliability, accuracy, and functionality were overstated, and the company downplayed the severity of issues related to the G7 devices [3]. - The lawsuit suggests that these actions increased the risk of regulatory scrutiny and could lead to significant legal, reputational, and financial harm for DexCom [3]. Group 2: Class Action Details - The class period for the lawsuit is defined as January 8, 2024, to September 17, 2025, with a deadline for shareholders to register as lead plaintiffs by December 26, 2025 [3][4]. - Shareholders who register will receive updates on the case's progress through a portfolio monitoring software, and participation in the case incurs no cost or obligation [4]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and illegal business practices [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who have suffered losses due to misleading statements or omissions [5].